secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2023-10-23T23:59:59+00:00
Accession:  0001193125-23-260299
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines reports Phase 1/1b data for RMC-6236 in NSCLC and PDAC; plans Phase 3 in 2024
--------------------------------------------------------------------------------

- RMC-6236 showed ORR 38% (DCR 85%) in evaluable NSCLC (n=40) and ORR 20% (DCR 87%) in PDAC (n=46) as of Oct 12, 2023.
- Safety at ≥80 mg daily: mostly Grade 1-2 rash/GI events; one Grade 4 perforation led to discontinuation; no fatal TRAEs.
- Company plans global randomized Phase 3 trial of RMC-6236 vs docetaxel in RAS-mutated NSCLC, aiming to start in 2024.
- Potential Phase 3 vs physician's choice in PDAC and combo pivotal trials also planned, pending further data and regulatory feedback.
- RMC-4630 combo with sotorasib showed additive toxicity without sufficient benefit; no further development for that combination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312523260299/0001193125-23-260299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312523260299/d567415d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-260299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer